Patil et al’s phase II study of seribantumab in tumors harboring NRG1 fusions supports the anti-tumor activity and safety of seribantumab in patients with advanced solid tumors harboring NRG1 fusions. Read the full article. ascopubs.org/doi/abs/10.1...

Nassar et al’s study demonstrates high concordance of Recurrence Score® (RS) results between paired core needle biopsy (CNB) and surgical excision (SE) samples, which supports use of CNB for Oncotype DX® testing. Read the full article. ascopubs.org/doi/abs/10.1... #BreastCancer #bcsm

Listen to the latest #ASCO #JCO Cancer Stories: The Art of Oncology with host @mikkaelsekeres.bsky.social. In this episode "Smell” with Dr. Cusick shares a connection to a cancer patient manifested as a scent. 🎧: ascopubs.org/do/smell-sce...

Simultaneous publication at #SABCS25! Horimoto et al.'s real-world data explores the clinical relevance of HER2 mutations in the efficacy of Trastuzumab Deruxtecan for HER2-low metastatic breast cancer. 👉 See the analysis: ascopubs.org/doi/abs/10.1... #BreastCancer

🚨 HER2+ MBC Maintenance News! 🚨 The Phase 3 HER2CLIMB-05 trial (Dieras et al.) was simultaneously published at #SABCS25. This study assesses Tucatinib vs. Placebo with Trastuzumab/Pertuzumab as first-line maintenance. 👉 See the results: ascopubs.org/doi/abs/10.1... #HER2Positive #BreastCancer

🎧 New #JCOAfterHours episode! Dr. Davide Soldato sits down with Dr. Andrea Necchi & Dr. Ashish Kamat to discuss their @ascocancer.bsky.social article on evolving end points for non-operative #MIBC trials and bladder-sparing strategies. Listen here: ascopubs.org/do/milan-con...

New data may reshape early-stage Triple-Negative Breast Cancer (TNBC) care! Simultaneous publication at #SABCS25: The Phase III RJBC 1501 trial (Shen et al.) confirms/challenges the role of Carboplatin in adjuvant EC Taxane. 👉 Read the results: ascopubs.org/doi/abs/10.1... #TNBC #BreastCancer

🚨 NEW DATA ALERT! 🚨 The Phase III BRUIN CLL-313 trial (Pirtobrutinib vs. BR) in untreated CLL/SLL was presented for simultaneous publication at #ASH25! You won't want to miss this! Learn more: ascopubs.org/doi/abs/10.1... #CLL #SLL

“Multidisciplinary care for a patient who's diagnosed with cancer while pregnant is essential.” In this “Science in Seconds,” Dr. Ann Partridge & Dr. Alison Loren discuss our first guideline on cancer during pregnancy. Read the guideline in @jco-asco.bsky.social: brnw.ch/21wYhKr

The first-ever Phase III randomized showdown is here! See results of pirtobrutinib vs. ibrutinib in treatment-naïve and R/R patients. Is the non-covalent BTKi the game-changer we’ve waited for? #ASH25 simultaneous publication with Woyach et al. is LIVE: brnw.ch/21wYbdz

The new AL International Staging System (AL-ISS) is here, defining Stage IIIC as an ultra-poor risk. Simultaneous publication at #ASH25! This is a major step for diagnosis and patient care. 👉 Read the full abstract: brnw.ch/21wYb73 #ALamyloidosis #Hematology

Pennsylvania Farmers & Skin Health: Unpacking the link between specific agricultural practices and melanoma incidence in the Keystone State. Learn more: brnw.ch/21wXMUK

"I was lucky. I had good insurance, I lived in LA, I was treated at 4 big cancer centers.   I speak to patients who if they don't go to work today, they don't get a paycheck. They can't miss a day to travel 8 hours to go see a specialist." 🎙️New @ascocancer.bsky.social @jco-asco.bsky.social podcast:

Check out #JCOGO's new article, discussing implementation of geriatric assessment in resource-constrained settings and some outstanding implementation questions and concerns. Learn more: brnw.ch/21wXieA

Check out the article in JCO on the Metformin Active Surveillance Trial in Low-Risk Prostate Cancer. Learn about the latest research on this common drug's potential role in managing prostate cancer: brnw.ch/21wX6DG

Publish with JCO GO or JCO OA. Advantages of fully #OpenAccess journals include: More citations & downloads Greater engagement A wider opportunity to advance cancer care globally Compliance with funder mandates With International #OAWeek coming up, learn how you can expand your reach.

Listen to the latest @ascocancer.bsky.social #JCO Cancer Stories: The Art of Oncology episode "A Fight Bigger Than Myeloma” with host Dr. Mikkael Sekeres & Dr. Adeel Khan who uses pt's multiple myeloma story to highlight civil liberties progress & the work still ahead. 🎧: brnw.ch/21wWO0S #mmsm

We encourage all AI submissions, but JCO will prioritize studies that demonstrate clinical impact. Read more in our guide: Bringing Trustworthy Artificial Intelligence to the Clinical Forefront at JCO: A Guide for Studies Testing Artificial Intelligence Models: brnw.ch/21wWuAG

Meet the dedicated leaders of our journals! Introducing the Editors-in-Chief for JCO Clinical Cancer Informatics, JCO Precision Oncology, and JCO Oncology Advances. They deliver authoritative, peer-reviewed content that is shaping the future of cancer research.

Meet our Editors-in-Chief! These leaders guide JCO, JCO Oncology Practice, and JCO Global Oncology to ensure you get the most credible, authoritative, and peer-reviewed oncology content. Their mission: informing high-quality patient care across the globe.

Check out #JCOGO's article "Understanding Barriers to Clinical Cancer Research in the Asia-Pacific." ➡️ brnw.ch/21wW8fC

💡Check out this IAEA update on radiotherapy resources in Central Asia. ascopubs.org/doi/10.1200/... @jco-asco.bsky.social @iaeaorg.bsky.social

Terrific (&entertaining) piece by @jco-asco.bsky.social OP editor @ethicsdoctorp.bsky.social on what he thinks AI could do to transform oncology practice by 2035. OK Computer! Reflections on How Artificial Intelligence Saved Cancer Care | JCO Oncology Practice ascopubs.org/doi/full/10....

We're thrilled to be here on BlueSky to bring you the latest practice-changing oncology research from all six JCO Journals! Follow-us for great content from #JCO, #JCOOP, #JCOGO, #JCOPO, #JCOCCI, & #JCOOA.